WO2020018053A3 - Comprimé comprenant du dasatinib - Google Patents

Comprimé comprenant du dasatinib Download PDF

Info

Publication number
WO2020018053A3
WO2020018053A3 PCT/TR2019/050377 TR2019050377W WO2020018053A3 WO 2020018053 A3 WO2020018053 A3 WO 2020018053A3 TR 2019050377 W TR2019050377 W TR 2019050377W WO 2020018053 A3 WO2020018053 A3 WO 2020018053A3
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
tablet
pharmaceutically acceptable
acceptable salt
relates
Prior art date
Application number
PCT/TR2019/050377
Other languages
English (en)
Other versions
WO2020018053A2 (fr
Inventor
Irem Yenice
Ali Ihsan SECKIN
Yuksel TOPALOGLU
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020018053A2 publication Critical patent/WO2020018053A2/fr
Publication of WO2020018053A3 publication Critical patent/WO2020018053A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un comprimé pharmaceutique comprenant du dasatinib ou un sel pharmaceutiquement acceptable de celui-ci et un enrobage non réactif.
PCT/TR2019/050377 2018-05-25 2019-05-24 Comprimé comprenant du dasatinib WO2020018053A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201807476 2018-05-25
TR2018/07476 2018-05-25

Publications (2)

Publication Number Publication Date
WO2020018053A2 WO2020018053A2 (fr) 2020-01-23
WO2020018053A3 true WO2020018053A3 (fr) 2020-03-26

Family

ID=69163921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050377 WO2020018053A2 (fr) 2018-05-25 2019-05-24 Comprimé comprenant du dasatinib

Country Status (1)

Country Link
WO (1) WO2020018053A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592680A (en) * 2020-03-06 2021-09-08 Zentiva Ks Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1885339B1 (fr) * 2005-05-05 2015-07-29 Bristol-Myers Squibb Holdings Ireland Formulations d'inhibiteur de src/abl
WO2017103057A1 (fr) * 2015-12-16 2017-06-22 Synthon B.V. Composition pharmaceutique comprenant du dasatinib anhydre
JP2019116435A (ja) * 2017-12-27 2019-07-18 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1885339B1 (fr) * 2005-05-05 2015-07-29 Bristol-Myers Squibb Holdings Ireland Formulations d'inhibiteur de src/abl
WO2017103057A1 (fr) * 2015-12-16 2017-06-22 Synthon B.V. Composition pharmaceutique comprenant du dasatinib anhydre
JP2019116435A (ja) * 2017-12-27 2019-07-18 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FELTON, LINDA A. ET AL.: "An update on pharmaceutical film coating for drug delivery", EXPERT OPINION ON DRUG DELIVERY, vol. 10, no. 4, 23 January 2013 (2013-01-23) - April 2013 (2013-04-01), pages 421 - 435, XP055693510 *

Also Published As

Publication number Publication date
WO2020018053A2 (fr) 2020-01-23

Similar Documents

Publication Publication Date Title
EP4233846A3 (fr) Formulations pharmaceutiques
EP3481831A4 (fr) Nouveaux dérivés de 4-aminopyrazolo [3,4-d]pyrimidinylazabicyclo et compositions pharmaceutiques les contenant
EP3894398A4 (fr) 3,3-difluoroallylamines ou leurs sels et compositions pharmaceutiques les comprenant
EP4041734A4 (fr) Nouveaux dérivés ayant une fraction 1,2,3,4-tétrahydronaphtalène ou un sel pharmaceutiquement acceptable de ceux-ci et compositions pharmaceutiques les comprenant
EP4041733A4 (fr) Nouveaux dérivés ayant une fraction 2,3-dihydro-1h-indène ou 2,3-dihydrobenzofurane ou un sel pharmaceutiquement acceptable de ceux-ci et compositions pharmaceutiques les comprenant
EP3768675A4 (fr) Nouveaux dérivés de triazolone ou leurs sels et compositions pharmaceutiques les comprenant
EP3894408A4 (fr) Triazolopyridin-3-ones ou leurs sels et compositions pharmaceutiques les comprenant
WO2019203771A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
WO2019194773A3 (fr) Combinaison contenant de la linagliptine et de la metformine
WO2019074826A3 (fr) Formulation de comprimé pharmaceutique bicouche
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
WO2019240699A3 (fr) Formulations de comprimés comprenant de la metformine et de la sitagliptine traitées par extrusion à chaud
EP3849992A4 (fr) Inhibiteurs de cd73 et utilisations pharmaceutiques associées
WO2020018053A3 (fr) Comprimé comprenant du dasatinib
EP3749289A4 (fr) Produit multiparticulaire comprenant des substances actives pharmaceutiques ou probiotiques
WO2020009675A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
EP3793586A4 (fr) Variants de type 1 du récepteur du complément soluble et utilisations associées
IL282999A (en) 4,3,1-oxadiazolone compound and drug
WO2019209217A3 (fr) Formulations à libération modifiée de flurbiprofène
WO2020139237A3 (fr) Formulation de comprimé bicouche d'atorvastatine calcique et d'ézétimibe
EP4079297A4 (fr) Formulation pharmaceutique comprenant de la cibenzoline ou un sel de celle-ci
EP4065598A4 (fr) Polypeptide conjugué à une fraction de biotine et composition pharmaceutique pour l'administration par voie orale le comprenant
EP3870149A4 (fr) Dérivés de décaline, procédé de préparation et composition pharmaceutique de ceux-ci
WO2019059868A3 (fr) Combinaisons pharmaceutiques de ténofovir, d'emtricitabine et d'éfavirenz
WO2019221684A3 (fr) Formulation de comprimé bicouche de fésotérodine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19838089

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19838089

Country of ref document: EP

Kind code of ref document: A2